This model contains ten-year commercial forecasts for hepatitis B drug sales by class, molecule and brand for the US, Japan, France, Germany, Italy, Spain, UK and Turkey. Reasons to Purchase - Understand the changing market dynamics of hepatitis B drugs, and success factors for leading brands.
- Assess the impact of events, such as patent expiries, on the overall hepatitis B market.
- Access global, country, class and product-specific forecasts for currently marketed drugs from 2009 to 2019, for seven major markets and Turkey.
Datamonitor
|